Long-Acting HIV Prevention

Long-acting HIV prevention is the [[GileadSciences|Gilead]] branch in vol.117.生物医药的2025：抄底中国、研发焦虑和新王继位. The episode says a twice-yearly injectable HIV-prevention drug showed complete prevention in a women’s clinical trial, making HIV feel closer to fully preventable and controllable.

The source stresses that the product is not a vaccine in mechanism, even if the long dosing interval and prevention effect can feel vaccine-like. Its wiki role is to contrast Gilead’s strong antiviral franchise with the same company’s more troubled oncology investment record.

Key Claims

• Long dosing intervals can change prevention practicality, not only pharmacology.
• The source distinguishes antiviral/prevention success from vaccine mechanism.
• Gilead’s HIV result is used as a counterweight to its CD47, TIGIT, and ADC oncology disappointments.
• The concept belongs to medical-product strategy, not personal medical advice.

Connections

• Gilead Sciences / 吉利德 - company example.
• Food and Drug Administration and Medical Risk Management - regulatory and safety-adjacent context.
• Multinational Pharma Patent-Cliff Anxiety - big-pharma pipeline-pressure backdrop.
• ADC Engineering Optimization - oncology contrast in the same company discussion.